Skip to main content

Advertisement

SpringerLink
Log in

Development of severe sclerotic chronic GVHD during treatment with dasatinib

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Breccia M, Cannella L, Stefanizzi C, Carotti A, Santopietro M, Alimena G . Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? [letter] Bone Marrow Transplant 2009; 44: 331–332.

    Article  CAS  PubMed  Google Scholar 

  2. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I . Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42: 757–760.

    Article  CAS  PubMed  Google Scholar 

  3. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719–722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114: 709–718.

    Article  CAS  PubMed  Google Scholar 

  5. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease [letter]. Blood 2009; 114: 3718–3719.

    Article  CAS  PubMed  Google Scholar 

  6. Aguilera DG, Tsimberidou AM . Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009; 5: 281–289.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214–2222.

    Article  CAS  PubMed  Google Scholar 

  8. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475–1484.

    Article  CAS  PubMed  Google Scholar 

  9. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308–1316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366–1377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors are employees of the United States Government, and, as such, this work was done in that capacity. The views expressed do not necessarily represent the views of the National Institutes of Health or the United States Government.

Author information

Authors and Affiliations

  1. Experimental Transplantation and Immunology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA

    D Pulanic, M R Bishop & S Z Pavletic

  2. Dermatology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA

    E W Cowen

  3. Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA

    K Baird

Authors
  1. D Pulanic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E W Cowen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Baird
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M R Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Z Pavletic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Pulanic.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pulanic, D., Cowen, E., Baird, K. et al. Development of severe sclerotic chronic GVHD during treatment with dasatinib. Bone Marrow Transplant 45, 1469–1470 (2010). https://doi.org/10.1038/bmt.2009.368

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.368

  • Springer Nature Limited

Search

Navigation